Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease - PubMed (original) (raw)
Comparative Study
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
C A McLean et al. Ann Neurol. 1999 Dec.
Abstract
Genetic evidence strongly supports the view that Abeta amyloid production is central to the cause of Alzheimer's disease. The kinetics, compartmentation, and form of Abeta and its temporal relation to the neurodegenerative process remain uncertain. The levels of soluble and insoluble Abeta were determined by using western blot techniques, and the findings were assessed in relation to indices of severity of disease. The mean level of soluble Abeta is increased threefold in Alzheimer's disease and correlates highly with markers of disease severity. In contrast, the level of insoluble Abeta (also a measure of total amyloid load) is found only to discriminate Alzheimer's disease from controls, and does not correlate with disease severity or numbers of amyloid plaques. These findings support the concept of several interacting pools of Abeta, that is, a large relatively static insoluble pool that is derived from a constantly turning over smaller soluble pool. The latter may exist in both intracellular and extracellular compartments, and contain the basic forms of Abeta that cause neurodegeneration. Reducing the levels of these soluble Abeta species by threefold to levels found in normal controls might prove to be a goal of future therapeutic intervention.
Similar articles
- Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Lue LF, et al. Am J Pathol. 1999 Sep;155(3):853-62. doi: 10.1016/s0002-9440(10)65184-x. Am J Pathol. 1999. PMID: 10487842 Free PMC article. - Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z. Zhang W, et al. Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14. Behav Brain Res. 2011. PMID: 21513747 - Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.
Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Kawarabayashi T, et al. J Neurosci. 2001 Jan 15;21(2):372-81. doi: 10.1523/JNEUROSCI.21-02-00372.2001. J Neurosci. 2001. PMID: 11160418 Free PMC article. - The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.
Wang ZX, Tan L, Liu J, Yu JT. Wang ZX, et al. Mol Neurobiol. 2016 Apr;53(3):1905-1924. doi: 10.1007/s12035-015-9143-0. Epub 2015 Apr 2. Mol Neurobiol. 2016. PMID: 25833098 Review. - Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.
Thal DR, Walter J, Saido TC, Fändrich M. Thal DR, et al. Acta Neuropathol. 2015 Feb;129(2):167-82. doi: 10.1007/s00401-014-1375-y. Epub 2014 Dec 23. Acta Neuropathol. 2015. PMID: 25534025 Review.
Cited by
- Soluble aβ promotes wild-type tau pathology in vivo.
Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM. Chabrier MA, et al. J Neurosci. 2012 Nov 28;32(48):17345-50. doi: 10.1523/JNEUROSCI.0172-12.2012. J Neurosci. 2012. PMID: 23197725 Free PMC article. - Enhanced neuronal degradation of amyloid-β oligomers allows synapse regeneration.
Bate C. Bate C. Neural Regen Res. 2015 May;10(5):700-1. doi: 10.4103/1673-5374.156955. Neural Regen Res. 2015. PMID: 26109937 Free PMC article. No abstract available. - A foldamer-dendrimer conjugate neutralizes synaptotoxic β-amyloid oligomers.
Fülöp L, Mándity IM, Juhász G, Szegedi V, Hetényi A, Wéber E, Bozsó Z, Simon D, Benkő M, Király Z, Martinek TA. Fülöp L, et al. PLoS One. 2012;7(7):e39485. doi: 10.1371/journal.pone.0039485. Epub 2012 Jul 30. PLoS One. 2012. PMID: 22859942 Free PMC article. - (18)F-florbetaben Aβ imaging in mild cognitive impairment.
Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chételat G, Raniga P, Mulligan RS, Salvado O, Putz B, Roth K, Masters CL, Reininger CB, Rowe CC. Ong K, et al. Alzheimers Res Ther. 2013 Jan 16;5(1):4. doi: 10.1186/alzrt158. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 23324163 Free PMC article. - Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
Johnson ECB, Ho K, Yu GQ, Das M, Sanchez PE, Djukic B, Lopez I, Yu X, Gill M, Zhang W, Paz JT, Palop JJ, Mucke L. Johnson ECB, et al. Mol Neurodegener. 2020 Sep 14;15(1):53. doi: 10.1186/s13024-020-00393-5. Mol Neurodegener. 2020. PMID: 32921309 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical